|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Interventions to improve sarcopenia in cirrhosis: A systematic review显示文摘BACKGROUND Sarcopenia, i.e., muscle loss is now a well-recognized complication of cirrhosis and in cases of non-alcoholic fatty liver disease can contribute to accelerate liver fibrosis leading to cirrhosis. Hence, it is imperative to study interventions which targets to improve sarcopenia in cirrhosis.AIM To examine the relationship between interventions such nutritional supplementation, exercise, combined life style intervention, testosterone replacement and trans jugular intrahepatic portosystemic shunt(TIPS) to improve muscle mass in cirrhosis.METHODS We search PubMed, EMBASE and Cochrane between June-August 2018, without a limiting period and the types of articles(RCTs, clinical trial, comparative study)in adult patients with sarcopenia and cirrhosis. The primary outcome of interest was improvement in muscle mass, strength and physical function interventions mentioned above. In the screening process, 154 full text articles were included in the review and 129 studies were excluded.RESULTS We identified 24 studies that met review inclusion criteria. The studies were diverse in terms of the design, setting, interventions, and outcome measurements.We performed only qualitative synthesis of evidence due to heterogeneity amongst studies. Risk of bias was medium in most of the included studies and low quality of evidence showed improvement in the muscle mass, strength and physical function following aerobic exercise. 60% of the included studies on the nutritional intervention, 100% of the studies on testosterone replacement in hypogonadal men and trans-jugular portosystemic shunt were proved to be effective in improving sarcopenia in cirrhosis.CONCLUSION Although the quality of evidence is low, the findings of our systematic review suggest improvement in the sarcopenia in cirrhosis with exercise, nutritional interventions, hormonal and TIPS interventions. High quality randomized controlled trials needed to further strengthen these findings. | Maliha Naseer Erica P Turse Ali Syed Francis E Dailey Mallak Zatreh Veysel Tahan | 2019 | World Journal of Clinical Cases2019，7，2： | 8 |
| 2 | Epidemiology,determinants,and management of AIDS cholangiopathy:A review显示文摘Diseases of the liver and biliary tree have been described with significant frequency among patients with human immunodeficiency virus(HIV), and its advanced state, acquired immunodeficiency syndrome(AIDS). Through a variety of mechanisms, HIV/AIDS has been shown to affect the hepatic parenchyma and biliary tree, leading to liver inflammation and biliary strictures. One of the potential hepatobiliary complications of this viral infection is AIDS cholangiopathy, a syndrome of biliary obstruction and liver damage due to infection-related strictures of the biliary tract. AIDS cholangiopathy is highly associated with opportunistic infections and advanced immunosuppression in AIDS patients, and due to the increased availability of highly active antiretroviral therapy, is now primarily seen in instances of poor access to antiretroviral therapy and medication non-compliance. While current published literature describes well the clinical, biochemical, and endoscopic management of AIDS-related cholangiopathy, information on its epidemiology, natural history, and pathology are not as well defined. The objective of this review is to summarize the available literature on AIDS cholangiopathy, emphasizing its epidemiology, course of disease, and determinants, while also revealing an updated approach for its evaluation and management. | Maliha Naseer Francis E Dailey Alhareth Al Juboori Sami Samiullah Veysel Tahan | 2018 | World Journal of Gastroenterology2018，24，7： | 5 |
| 3 | Adrenomedullin in cirrhotic and non-cirrhotic portal hypertension显示文摘AIM:Adrenomedullin (ADM) is a potent vasodilator peptide.ADM and nitric oxide (NO) are produced in vascular endothelial cells. Increased ADM level has been linked to hyperdynamic circulation and arterial vasodilatation in cirrhotic portal hypertension (CPH). The role of ADM in non-cirrhotic portal hypertension (NCPH) is unknown, plasma ADM levels were studied in patients with NCPH, compensated and decompensated cirrhosis in order to determine its contribution to portal hypertension (PH) in these groups.METHODS: There were 4 groups of subjects. Group 1consisted of 27 patients (F/M: 12/15) with NCPH due to portal and/or splenic vein thrombosis (mean age: 41±12years), group 2 consisted of 14 patients (F/M: 6/8) with compensated (Child-Pugh A) cirrhosis (mean age: 46±4),group 3 consisted of 16 patients (F/M: 6/10) with decompensated (Child-Pugh C) cirrhosis (mean age: 47±12).Fourteen healthy subjects (F/M: 6/8) (mean age: 44±8) were used as controls in Group 4. ADM level was measured by ELISA. NO was determined as nitrite/nitrate level by chemoluminescence.RESULTS: Adl level in Group 11 (236±61.4 pg/mL) was significantly higher than that in group 2 (108.4±28.3 pg/mL)and group 4 (84.1±31.5 pg/mL) (both P<0.0001) but was lower than that in Group3 (324±93.7 pg/mL) (P=0.002). NO level in group 1 (27±1.4 μmol/L) was significantly higher than that in group 2 (19.8±2.8 μmol/L) and group 4 (16.9±1.6μmol/L) but was lower than that in Group 3 (39±3.6 μmol/L)(for all three P<0.0001). A strong correlation was observed between ADM and NO levels (r=0.827, P<0.0001).CONCLUSION: Adrenomedullin and NO levels were high in both non-cirrhotic and cirrhotic portal hypertension and were closely correlated, Adrenomedullin and NO levels increased proportionally with the severity of cirrhosis, and were significantly higher than those in patients with NCPH.Portal hypertension plays an important role in the increase of ADM and NO. Parenchymal damage in cirrhosis may contribute to the increase in these parameters. | V Tahan E Avsar C Karaca E Uslu F Eren S Aydin H Uzun HO Hamzaoglu F Besisik C Kalayci A Okten N Tozun | 2003 | World Journal of Gastroenterology2003，9，10： | 5 |
| 4 | Effects of rosiglitazone on methionine--choline deficient diet--induced nonalcoholic steatohepatitis显示文摘 | Tahan V Imeryuz N Avsar E | 2007 | Hepatology2007，46，6： | 1 |
| 5 | Montelukast inhibitstumour necrosis factor-alpha-mediated interleukin-8 expressionthrough inhibition of nuclear factor-kappaB p65-associated histoneacetyltransferase activity显示文摘 | Tahan F Jazrawi E Moodley T | 2008 | Clin Exp Allerg2008，38，5： | 1 |
| 6 | Establishing quality performance of distribution companies based on Yardstick regulation显示文摘 | Tanure J E P dos S Tahan C M V Lima J W M | 2006 | IEEE Trans on Power Systems2006，21，3： | 1 |
| 7 | Montelukast inhibits tumour nec-rosis factor-alpha-mediated interleukin-8 expression through inhibitionof nuclear factor-kappaB p65-associated hi stone acetyltransferaseactivity 显示文摘 | Tahan F Jazrawi E Moodley T | 2008 | Clin Exp Allergy2008，38，5： | 1 |
| 8 | Montelukast inhibits tumour necrosis factor-alpha-mediated interleukin-8 expression through inhibition of nuclear factor-kappa B p65-associated histone acetyltransferase activity显示文摘 | Tahan F Jazrawi E Moodley T | 2008 | Clin Exp Allergy2008，38，5： | 1 |
| 9 | Effects of rosiglitazone on me- thioninecholine diet -induced nonalcoholic eteatohepatitivs 显示文摘 | Tahan V Imerya Z N Avsar E | 2007 | Hepatology2007，46，6： | 1 |
| 10 | Rosiglitazone attenuates liver inflammation in a rat model of nonalcoholic steatohepatitis 显示文摘 | Tahan V Eren F Avsar E | 2007 | Dig Dis Sci2007，52，： | 1 |
| 11 | Dissimilar friction welding of 6061- T6 aluminum and AISI 1018 steel: properties and microstructural characterization显示文摘 | Tahan E Gould J E John C L | 2010 | Materials and Design2010，31，： | 1 |
| 12 | Rosiglitazone attenuates liver inflam- mation in a rat model of nonalcoholic steatohePatitis显示文摘 | Tahan V Eren F Avsar E | 2007 | Digestive Dis- eases and Sciences2007，52，12： | 1 |
| 13 | Electrothermal atomic absorption spectrometric determination of A1, Cu, Fe, Pb, V and Zn in clinical samples and in certified environmental reference ma- terials显示文摘 | Tahan J E Granadillo V A Romero R A | 1994 | Anal Chim Acta1994，295，12： | 1 |
| 14 | Rosiglitazone attenuates liver inflammation in a rat model of nonalcoholic steatohepatitis 显示文摘 | Tahan V Eren F Avsar E | 2007 | Dig Dis Sci2007，52，12： | 1 |
| 15 | Montelukast inhibits tumour necrosis factor-alpha-mediated interleukin-8 expres- sion through inhibition of nuclear factor-kappaB p65- associated hiatone acetyltransferase activity显示文摘 | Tahan F Jazrawi E Moodley T | 2008 | Clin Exp Allergy2008，38，5： | 1 |
| 16 | The Influence of the Blood Levels of Lead, Aluminum and Vanadium Upon the Arterial Hypertension显示文摘 | Granadillo V A Tahan J E Salgado O | 1995 | Clin Chem Aeta1995，233，12： | 1 |
| 17 | Distribution Transformer Loading Evaluation Based on Load Profiles Measurements 显示文摘 | Jardini J A Tahan C M V Ahn S U Ferrari E L | 1997 | IEEE Transactions on Power Delivery1997，12，4： | 1 |
| 18 | Establishing quality performance of distribution companies based on Yardstick regulation显示文摘 | Tanure J E P dos S Tahan C M V Lima J W M | 2006 | IEEE Trans on Power Systems2006，21，3： | 1 |
| 19 | Modelling the behaviour of oil spills in ice-infested waters 显示文摘 | Venkatesh S Tahan H E Comfort G | 1990 | Atmosphere Ocean1990，28，33： | 1 |
| 20 | One more chance of fistula healing in inflammatory bowel disease:Stem cell therapy显示文摘Patients with fistulizing inflammatory bowel disease are traditionally difficult to treat. This patient population often experiences delayed or insufficient healing of fistulas using current standard regimens including anti-biotics, immunomodulators, anti-tumor necrosis factor--α drug, placement of setons, and surgical repair. Several studies over the last ten to fifteen years have been conducted using stem cell therapies with promising results in this patient population. These studies show stem cell therapy in fistulizing disease to be successful in healing between 60%--88% compared to currently 50% with infliximab. Moreover, remission was seen 24 wk to 52 wk in these studies. Further research with a multi--approach treatment using medications, stem cell therapy, and surgical interventions will likely be the future of this innovative treatment approach. | Erica P Turse Francis E Dailey Maliha Naseer Edward K Partyka Veysel Tahan | 2018 | World Journal of Clinical Cases2018，6，12： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员